Company news

Anavex Life Sciences Corp. news in 2019

Anavex Life Sciences Corp.'s news releases, calls and decks from 2019, newest first.

View company

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates

December 15, 2019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

December 9, 2019

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference

December 3, 2019

Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

November 13, 2019

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

November 5, 2019

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease

October 8, 2019

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

October 1, 2019

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

September 25, 2019

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

September 15, 2019

Decks in 2019